Comprehensive proteomics and meta-analysis of COVID-19 host response.

Comprehensive proteomics and meta-analysis of COVID-19 host response.

Publication date: Sep 22, 2023

COVID-19 is characterised by systemic immunological perturbations in the human body, which can lead to multi-organ damage. Many of these processes are considered to be mediated by the blood. Therefore, to better understand the systemic host response to SARS-CoV-2 infection, we performed systematic analyses of the circulating, soluble proteins in the blood through global proteomics by mass-spectrometry (MS) proteomics. Here, we show that a large part of the soluble blood proteome is altered in COVID-19, among them elevated levels of interferon-induced and proteasomal proteins. Some proteins that have alternating levels in human cells after a SARS-CoV-2 infection in vitro and in different organs of COVID-19 patients are deregulated in the blood, suggesting shared infection-related changes. The availability of different public proteomic resources on soluble blood proteome alterations leaves uncertainty about the change of a given protein during COVID-19. Hence, we performed a systematic review and meta-analysis of MS global proteomics studies of soluble blood proteomes, including up to 1706 individuals (1039 COVID-19 patients), to provide concluding estimates for the alteration of 1517 soluble blood proteins in COVID-19. Finally, based on the meta-analysis we developed CoViMAPP, an open-access resource for effect sizes of alterations and diagnostic potential of soluble blood proteins in COVID-19, which is publicly available for the research, clinical, and academic community.

Open Access PDF

Concepts Keywords
Leaves Alterations
Organ Analysis
Proteomics Blood
Spectrometry Covid
Global
Host
Infection
Meta
Performed
Proteome
Proteomics
Sars
Soluble
Systematic
Systemic

Semantics

Type Source Name
disease MESH COVID-19
disease IDO host
disease VO organ
disease IDO blood
drug DRUGBANK Tropicamide
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH uncertainty
disease MESH cytokine storm
disease MESH Infectious Diseases
drug DRUGBANK L-Alanine
pathway KEGG Purine metabolism
disease MESH shock
disease VO gene
drug DRUGBANK Pidolic Acid
pathway KEGG Fatty acid metabolism
disease MESH inflammation
drug DRUGBANK Trestolone
drug DRUGBANK Angiotensin II
disease VO URE
disease IDO site
disease MESH carcinoma
drug DRUGBANK Trypsin
drug DRUGBANK L-Lysine
disease VO Glycoprotein
drug DRUGBANK Methylergometrine
disease MESH Hypertension
disease MESH Asthma
pathway KEGG Asthma
disease MESH Viremia
disease VO Rho
disease MESH Critically ill
disease MESH Fatal outcome
drug DRUGBANK Anakinra
drug DRUGBANK Chloroquine
disease MESH heart disease
disease MESH pulmonary disease
disease MESH kidney disease
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)